

This educational event is organised and funded by GSK
For healthcare professionals and members of the scientific and public policy community only

Respiratory syncytial virus burden in older adults and the potential role of prevention in strengthening European healthcare systems

Join our experts as they explore the burden of respiratory syncytial virus (RSV) in older adults. Our panellists will present results from research exploring patients' and physicians' knowledge, attitudes and preference towards RSV vaccination, and will seek to quantify its potential public health impact on healthcare systems in Europe. This will be followed by a panel discussion.

Time	Session	Presenter
12:55–13:00	Introduction	Dr Jane Barratt Global Advisor at the International Federation on Ageing, Toronto, Ontario, Canada
13:00–13:10	Presentation 1: Results from research exploring patients' and physicians' knowledge, attitudes and preferences towards RSV vaccination	Dr Tommi Tervonen Chief Scientist at Kielo Research, Switzerland
13:10–13:20	Presentation 2: Results of cost-effectiveness modelling research with a focus on the potential public health impact of RSV vaccination in older adults on healthcare systems in Europe	Dr Xiao Li Senior researcher at the Centre for Health Economic Research and Modelling of Infectious Diseases, University of Antwerp, Belgium
13:20–13:50	Panel discussion Exchange expert perspectives on the potential benefits of an RSV vaccination programme on healthcare systems in Europe	<ul style="list-style-type: none">• Prof. Filipe Froes Pulmonologist at the Centro Hospitalar Lisboa Norte/ULSSM, Lisbon, Portugal• Dr Tommi Tervonen• Dr Xiao Li• Dr Jane Barratt
13:50–13:55	Closing	Dr Jane Barratt

Para mais informações e em caso de suspeita de um acontecimento adverso ou de outra informação de segurança, contactar o Departamento Médico da GSK +351 214129500 ou enviar um email para lis.nucleo-farmacovigilancia@gsk.com

If you are professionally active in a country other than Portugal, adverse events should be reported to the appropriate health authority in your country

Adverse events should be reported. In the UK, reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for

MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on +44(0)800 221 441 or UKSafety@GSK.com

© 2024 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium

NX-GBL-RSA-AGND-240004 | October 2024

